CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical ...

Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% ...

Learn more about whether Alvotech or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which ...

Its product portfolio comprises Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. Thus, its product ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following yesterday’s topline data from the Batoclimab ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy.In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against the other best ...

Pantheon Vision and Eyedeal Medical collaborate to commercialize bioengineered corneal implants, targeting corneal blindness elimination. Pantheon has engaged in multiple FDA meetings to support a ...

Alcon's acquisition of Aurion Biotech enhances its cell therapy capabilities for eye diseases, with Aurion operating independently under Alcon's support. Aurion's AURN001, an allogeneic cell therapy ...